Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study

Journal of Surgical Oncology

Volumn 109, Issue 6, 2014, Pages 580-585

  Wang, Ling Wei ^a   Hsiao, Chin Fu ^b   Chen, William Tzu Liang ^c   Lee, Hao Hsien ^d   Lin, Tzu Chen ^e   Chen, Hung Chang ^f   Chen, Hong Hwa ^g   Chien, Chun Ru ^c   Lin, Tze Yi ^c   Liu, Tsang Wu ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Division of Infectious Disease   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

celecoxib; chemoradiotherapy; COX 2; rectal cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN T; CELECOXIB; CREATININE; CYCLOOXYGENASE 2; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; HEMOGLOBIN; OXALIPLATIN; TEGAFUR URACIL; UFT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ANAL PAIN; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DYSURIA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADICAL RESECTION; RASH; RECTUM CANCER; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; URINARY FREQUENCY; VOMITING; WEIGHT REDUCTION;

CELECOXIB; CHEMORADIOTHERAPY; COX-2; RECTAL CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PYRAZOLES; RECTAL NEOPLASMS; RECTUM; SULFONAMIDES; TEGAFUR; URACIL;

EID: 84898811414     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23538     Document Type: Article

References (35)

1. Chan A, Wong A, Langevin J, et al.: Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 791-799.
2. Chen ET, Mohiuddin M, Brodovsky H, et al.: Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994; 30: 169-175.
3. Videtic GM, Fisher BJ, Perera FE, et al.: Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1998; 42: 319-324.
4. Janjan NA, Khoo VS, Abbruzzese J, et al.: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-1038.
5. Minsky BD:, Sphincter preservation in rectal cancer. Preoperative radiation therapy followed by low anterior resection with coloanal anastomosis. Semin Radiat Oncol 1998; 8: 30-35.
6. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987.
7. Ceelen W, Fierens K, Van Nieuwenhove Y, et al.: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: A systematic review and meta-analysis. Int J Cancer 2009; 124: 2966-2972.
8. Uzcudun AE, Batlle JF, Velasco JC, et al.: Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: Results from a phase II study. Dis Colon Rectum 2002; 45: 1349-1358.
9. Fernandez-Martos C, Aparicio J, Bosch C, et al.: Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: A phase II multicenter study with 3 years' follow-Up. J Clin Oncol 2004; 22: 3016-3022.
10. Wang LW, Yang SH, Lin JK, et al.: Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer. J Surg Oncol 2005; 89: 256-263; discussion 263-254.
11. Gallo O, Franchi A, Magnelli L, et al.: Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3: 53-61.
12. Smith FM, Reynolds JV, Kay EW, et al.: COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 2006; 64: 466-472.
13. Higuchi T, Iwama T, Yoshinaga K, et al.: A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9: 4756-4760.
14. Shin YK, Park JS, Kim HS, et al.: Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005; 65: 9501-9509.
15. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
16. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
17. Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884.
18. Debucquoy A, Roels S, Goethals L, et al.: Double blind randomized phase II study with radiation + 5-fluorouracil +/- celecoxib for resectable rectal cancer. Radiother Oncol 2009; 93: 273-278.
19. Unger KR, Romney DA, Koc M, et al.: Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. Int J Radiat Oncol Biol Phys 2011; 80: 1377-1382.
20. Jakobsen A, Mortensen JP, Bisgaard C, et al.: A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: A phase II trial. Int J Colorectal Dis 2008; 23: 251-255.
21. Malik I, Hussein F, Bush D, et al.: A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. Am J Clin Oncol 2010; 33: 242-245.
22. Ryan R, Gibbons D, Hyland JM, et al.: Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47: 141-146.
23. Mehta VK, Poen J, Ford J, et al.: Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 2001; 44: 52-58.
24. Sanghera P, Wong DW, McConkey CC, et al.: Chemoradiotherapy for rectal cancer: An updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol) 2008; 20: 176-183.
25. Huh JW, Kim HR, Kim YJ:, Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum 2013; 56: 698-703.
26. Sloothaak DA, Geijsen DE, van Leersum NJ, et al.: Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013; 100: 933-939.
27. Bouzourene H, Bosman FT, Seelentag W, et al.: Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002; 94: 1121-1130.
28. Rodel C, Martus P, Papadoupolos T, et al.: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
29. de Heer P, Gosens MJ, de Bruin EC, et al.: Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 2007; 13: 2955-2960.
30. Bouzourene H, Yan P, Sandmeier D, et al.: The role of COX-2 in rectal cancer treated with preoperative radiotherapy. Virchows Arch 2008; 452: 499-505.
31. Tomozawa S, Tsuno NH, Sunami E, et al.: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83: 324-328.
32. Jang TJ, Jeon KH, Jung KH:, Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. Yonsei Med J 2009; 50: 818-824.
33. Kim JW, Kim YB, Choi JJ, et al.: Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 84: e577-e584.
34. Kakiuchi Y, Tsuji S, Tsujii M, et al.: Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002; 62: 1567-1572.
35. Roh JL, Sung MW, Park SW, et al.: Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 2004; 64: 3230-3235.